Research shows double HIV regimen has comparable efficacy to triple therapy
GSK announced “positive” results from a study comparing the efficacy of the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) to the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in managing virologically-suppressed adults living with HIV. Both regimens are administered as a single tablet per…
